Clinical Trial

Moleculin Participates in Virtual Investor “What This Means” Segment

Watch the “What This Means" segment here HOUSTON, June 18, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin”…

6 months ago

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old…

6 months ago

NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role

Vancouver, British Columbia--(Newsfile Corp. - June 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company…

6 months ago

Vivalink’s Biometrics Data Platform Powers Innovative Study on How Urban Green Spaces Impact Mental and Physical Health

University of Louisville researchers use Vivalink's wearable technologies and data platform to measure how urban green spaces impact physical and…

6 months ago

One2Treat, the leading company incorporating the patient voice into clinical development, launches One2Treat Voice app

LOUVAIN-LA-NEUVE, Belgium, June 17, 2025 /PRNewswire/ -- One2Treat SA, a fast-growing tech company incorporating the patient voice in all strategic decisions…

6 months ago

Ratio Therapeutics and Nusano Enter Long-Term, Multi-Isotope Supply Agreement to Boost Production of Cancer Radiopharmaceuticals

Agreement provides Ratio access to Nusano-produced radioisotopes for oncology diagnostics and therapeuticsAccelerates Ratio's clinical pipeline with copper-64 for PET imaging and…

6 months ago

Hemostemix Closes Private Placement of $469,366

Calgary, Alberta--(Newsfile Corp. - June 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")…

6 months ago

Kamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle East

REHOVOT, Israel and HOBOKEN, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical…

6 months ago

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

Dr. Pruthi brings vast clinical development experience advancing novel therapies for NMIBC to Relmada and the NDV-01 program Phase 3…

6 months ago